According to Zacks, “Aimmune Therapeutics, Inc. is a biopharmaceutical company which is engaged in the development of desensitization treatments for peanut and other food allergies. The Company’s characterized oral desensitization immunotherapy includes AR101, a product for the treatment of peanut allergy in children and adults which is in clinical trial stage. Aimmune Therapeutics, Inc. is headquartered in Brisbane, California. “
A number of other equities research analysts have also weighed in on the stock. Wedbush decreased their price objective on shares of Aimmune Therapeutics from $80.00 to $76.00 and set an “outperform” rating for the company in a report on Tuesday, March 19th. BidaskClub downgraded shares of Aimmune Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Tuesday, April 23rd. Cantor Fitzgerald set a $45.00 target price on shares of Aimmune Therapeutics and gave the company a “buy” rating in a research report on Thursday, February 28th. Finally, Credit Suisse Group initiated coverage on shares of Aimmune Therapeutics in a research report on Tuesday, May 21st. They set an “outperform” rating and a $30.00 target price on the stock. Five analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The company has an average rating of “Hold” and an average target price of $46.43.
Aimmune Therapeutics (NASDAQ:AIMT) last announced its quarterly earnings data on Wednesday, May 8th. The biotechnology company reported ($0.87) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.94) by $0.07. Research analysts forecast that Aimmune Therapeutics will post -3.77 EPS for the current fiscal year.
Hedge funds and other institutional investors have recently bought and sold shares of the business. Cable Hill Partners LLC increased its position in Aimmune Therapeutics by 81.7% during the 1st quarter. Cable Hill Partners LLC now owns 1,112 shares of the biotechnology company’s stock valued at $25,000 after purchasing an additional 500 shares during the period. Manchester Capital Management LLC purchased a new position in Aimmune Therapeutics during the 1st quarter valued at about $27,000. Pearl River Capital LLC purchased a new position in Aimmune Therapeutics during the 1st quarter valued at about $28,000. Marshall Wace North America L.P. purchased a new position in Aimmune Therapeutics during the 1st quarter valued at about $32,000. Finally, Bank of Montreal Can increased its position in Aimmune Therapeutics by 47.9% during the 4th quarter. Bank of Montreal Can now owns 1,516 shares of the biotechnology company’s stock valued at $37,000 after purchasing an additional 491 shares during the period. 76.13% of the stock is currently owned by institutional investors and hedge funds.
About Aimmune Therapeutics
Aimmune Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies. Its lead Characterized Oral Desensitization ImmunoTherapy (CODIT) product candidate is AR101, an investigational biologic, which is in Phase III clinical trial for the treatment of patients with peanut allergy.
See Also: Net Asset Value
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.